ET
Energy Transfer LP Common UnitsstockNYSE
At CloseNov 16, 2026 3:59:55 PM EST
19.18USD-1.134%(-0.22)11,479,134
Pre-marketNov 16, 2026 9:20:30 AM EST
19.39USD-0.044%(-0.01)
After-hoursNov 16, 2026 4:59:30 PM EST
19.19USD+0.052%(+0.01)
ET Reddit Mentions by subreddit
Loading…
ET Mentions × sentiment
Loading…
ET Specific Mentions latest comments & posts
Thank you for sharing more about this. We will continue to evaluate this on our end. Since you are still experiencing trouble, we recommend contacting our Technical Support team. As noted in the response above, you can reach them Monday through Friday from 8:30 a.m. to 9:00 p.m. ET.
sentiment 0.784
**BanBet Created** ▼ | **Record:** 0W - 1L
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $153.00 (below) | $156.61 | -2.3% | Mon, Nov 23, 5:00 PM ET |
sentiment 0.250
Right, that's how all mutual funds work. They price once a day after the 4pm ET close, so your SWVXX sell gets that day's NAV. SWVXX holds its price at 1 dollar a share, so the timing barely matters for you here, but with a stock fund the price you get is the close, not whatever it was showing midday.
sentiment 0.031
**BanBet Created** ▼ | **Record:** 2W - 1L
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $140.49 (below) | $156.10 | -10.0% | Wed 4:00 PM ET |
sentiment 0.250
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $171.07 (above) | $155.52 | +10.0% | Thu 3:42 PM ET |
sentiment 0.250
[Thousands of Chase Bank customers](https://www.cnn.com/2026/11/16/business/bank-outage-chase-us-bank-bank-of-america?utm_medium=social&utm_campaign=missions&utm_source=reddit) reported they were unable to access their online accounts on Monday.
“Due to a technical issue, some transactions are taking longer than usual to complete but customers still have access to their accounts and funds,” a Chase spokesperson told CNN. “We are working to resolve this as quickly as possible.”
As of 2:00 pm ET, more than 4,700 customers reported issues with Chase, according to Downdetector.
Customers of other major banks reported issues, including Bank of America, Wells Fargo, and U.S. Bank, though at a smaller scale.
The reports with the other banks appears to be related to sending money through Zelle to Chase accounts, a digital payment network.
“U.S. Bank systems are not directly impacted. However, clients attempting to send or receive Zelle payments with another financial institution may experience transaction delays,” U.S. Bank said in a statement.
sentiment 0.710
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **SPY** | $746.00 (above) | $740.25 | +0.8% | Tue 2:21 PM ET |
sentiment 0.250
| Ticker | Target | Entry | Current | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|:---:|
| **SPY** ▼ | $720.00 (below) | $754.01 | $742.00 | -4.5% | Wed, Dec 2, 2:46 PM ET |
| **Record** | 0W - 1L | 0% | - | - | - |
sentiment 0.000
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $170.00 (above) | $157.79 | +7.7% | Thu 12:19 PM ET |
sentiment 0.250
42% profit, $500 profit. Upped number of contracts for today. I was watching the drop across the ETFs, on IWM, it tried its puny best to stay above 275, then failed miserably. It tried to recover. I was greedy, looking for $25 per contract in a short range movement of the price.
Why I did not get into puts on the drop and could have made more money? Part of my Christmas trading plan for this week is to try use a certain amount of money to trade. Some people call it risk management, money you can affort to lose and some other terms 🙇🏻♂️
There is no shortcut to trading, I spent a lot of time analysis, practicing, using my own real money to trade and come this stage. If you really want, all knowledge is free on the world wide web, same as all university courses full knowledge are free out there for since many years.
Don't be greedy like me. I am lazy and frustrated with myself sometimes 🙄 use money you can afford to lose.
I follow my plan, follow yours and do take a small profit, consistent, get used to the Christmas spirit. Let got of greed, boredom and hurriedness.
If you lost some money this month, you can see my previous post and get inspired by my pitiful small profits 😬 and know that if you keep consistency, it may be in your favour. Don't put more money, practice and wait for next month. Give yourself time.
**Total $2,715**
|Day|Little Profit $|
|:-|:-|
|16|500|
|15|250|
|14|300|
|13|210|
|12|334|
|11|122|
|10|110|
|9|200|
|8|100|
|7|125|
|6|120|
|5|70|
|4|82|
|3|52|
|2|60|
|1|80|
I can trade SPY, QQQ, SPX but I am not doing it as IWM fit my current Christmas trading strategy/plan, the premiums are more expensive these days. If you are unsure, sit on your hands.
I need money for Christmas gifts. No one is going to give me for free, I am not so beautiful. I started with a $250 account, aiming to reach $5k profit in 50 day/trades. You saw on many of my previous post I was growing another small account. Hope you get inspired. Life is short. I try post the trades.
Simple options strategy, no wheel, iron condors etc. Using simple EMAs, VWAP etc to see the trends, levels calculations.
Trade: 20 contracts = $500 total profit.
Total options cost = $1,200
42 % profit
Time in Trade : 19 min. Not a full morning glory trade 🙄
$10 per contract per day, it makes a huge difference with time. Don't be greedy every time.
My trading plan and strategy is trading one trade a day, 2-5 times a week depending on availability.
If you are learning by yourself, give it 2-3 months to see how you are progressing.
If you believe I am lucky every day with the trades and posts 🤷🏻♂️ so be it. I believe I have no choice, I put in the effort and keep doing, any loss is my loss as it is me executing my own trades and money.
I only day trade options on ETFs like SPY, QQQ, IWM etc. Timestamp on the broker is UK time. So, entry time of 3.31 is 10.31 ET.
I trade on my phone, screenshot is from TastyTrade. EMA 200 and VWAP on the screenshot for TradingView
sentiment 0.978
12 ET
sentiment 0.000
Upon notification of your passing, security measures will block access using your login credentials, but your spouse's credentials will remain active. Certain features will be temporarily deactivated during the transition, but the account itself will remain open. For specific details to help you plan, you can speak with our Life Events team to review and make any necessary plans. They are available Monday through Friday, 8:00 a.m. to 6:30 p.m. ET.
[Contact us](https://www.fidelity.com/customer-service/contact-us)
Please let me know if you need anything else.
sentiment 0.909
| Ticker | Target | Entry | Current | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|:---:|
| **SPY** ▼ | $730.00 (below) | $750.39 | $746.44 | -2.7% | Fri, Nov 27, 12:05 PM ET |
| **Record** | 5W - 0L | 100% | - | - | - |
sentiment 0.000
| Ticker | Target | Entry | Current | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|:---:|
| **SPY** ▲ | $785.00 (above) | $760.30 | $746.65 | +3.2% | Wed, Dec 2, 3:34 PM ET |
sentiment 0.000
Perhaps you had a bad entry. Shares alone up 110% the last five years even after this pullback. But since inception, ET has averaged at 16% total annual return. That’s pretty excellent.
Tax forms are what they are. Minor inconvenience, but there’s benefits in the tax deferral. If you just buy and hold long term, it’s an excellent compounder with tax advantages. $10k invested 20 years ago would be paying you over $10k a year today regardless of what the share price does. Cant beat that.
DCF has it about 50% undervalued. It should hit the low to mid $30’s by 2030-2032. At which point, their distribution will be over $2. Meaning an entry today will likely be yielding over a 10% annual yield on cost.
sentiment 0.969
SHORTING JPM CYBER ATTACK potentially
Yes, Chase is down. Plaid's own status page says Chase "is currently experiencing downtime impacting all channels." That means every way of reaching Chase, including the app, online banking and outside apps linked to your accounts, which Plaid connects. Its notice went up about 18 minutes ago. Downdetector shows reports since 9:53 AM ET, and people on X say card transactions are failing. Chase itself hasn't said anything yet, and nobody has specifically confirmed ATMs either way, but with card authorizations failing I'd expect withdrawals to fail too.
I'll recheck every 10 minutes and message you only when something changes, like Chase confirming the outage, word on ATMs, or the fix. The watch shuts off once it's resolved, or at 7 PM ET at the latest.
sentiment -0.803
I like energy but not ET. Had it for years, but always traded in a narrow range and the dividend/return wasn't worth it.
Plus the MLP tax headache; I hate K-1's, and their package was always notoriously late.
sentiment -0.696
**HELUS**
**Trial design**
PARADIGM is Helus’ Phase 3 program testing HLP003 as an add-on treatment for adults with MDD whose antidepressants haven’t worked well enough.
The program has two pivotal studies. APPROACH reported results this morning. EMBRACE is still recruiting, and its topline data are due in Q4 2027. In APPROACH, patients got either two 16 mg doses of HLP003 or placebo, with the doses spaced three weeks apart.
A subset of patients also continue into EXTEND, a long-term extension study. It offers open-label dosing or re-dosing to non-responders and to those who relapse, and should finish in 2028.
Both Phase 3 studies measure their primary endpoint at Week 6: change in MADRS from baseline versus placebo. The main design difference is the comparators. APPROACH, today’s readout, compares 16 mg with inert placebo only. EMBRACE compares 16 mg with both an 8 mg dose and inert placebo.
APPROACH’s intent-to-treat population was 222 adults with moderate-to-severe MDD (MADRS of 24 or higher): 112 received HLP003 and 110 received placebo. Average baseline MADRS was 32.7 in the drug arm and 33.8 in the placebo arm. Everyone kept taking their usual antidepressant for the whole study.
About 21.6% of participants said they had used psychedelics before, which is a fairly high proportion. Recent use was grounds for exclusion.
**Efficacy**
According to Helus, two 16 mg doses of its deuterated psilocin given three weeks apart cut MADRS scores by a statistically significant and clinically meaningful amount compared with inert placebo. The mean difference at Week 6 was -7.6 points.
The benefit seems durable. HLP003 beat placebo by 7.0 points at Week 12. The effect also came on quickly: after one dose, the gap was already 5.0 points at Day 2.
At Week 6, 56.3% of HLP003 patients responded (MADRS down at least 50% from baseline), compared with 28.2% on placebo. Remission (MADRS of 10 or below) was 50.9% versus 18.2%. At Week 12, response was 45.5% versus 19.1%, and remission was 40.2% versus 15.5%.
These rates compare well with those of already-approved adjunctive treatments.
A placebo-adjusted drop of -7.6 at Week 6 is a solid result. It is close to the -8.1 seen at the same time point in Emerge, Definium Therapeutics’ Phase 3 MDD study, which reported over the summer. However, Emerge used a single dosing session and gave the drug as monotherapy. As always, comparisons across trials need to be made and read carefully.
The placebo arm improved far more in Helus’ study than in Definium’s: MADRS fell 11.9 points at Week 6, against 5.2 points in Definium’s Phase 3 at the same point. Two possible reasons are that Helus’ design is adjunctive and that it involved two dosing visits.
Helus also wraps much more non-drug support around treatment than developers such as Definium or Compass. It uses a support framework called EMBARK. Helus says EMBARK takes established evidence-based treatments (EBTs) and pairs them with psychedelic-assisted psychotherapies that have been shown to work. Definium, for comparison, stresses that it only monitors patients. In principle, Helus’ heavier support could lift the placebo arm somewhat, although that didn’t happen in HLP003’s Phase 2 trial.
Either way, separating from placebo by 7.6 points on the primary endpoint, even with a strong placebo response, is an efficacy win for Helus.
CEO Michael Halstead had told investors that Helus treats a 4–5 point difference as the benchmark, pointing to adjunctive antipsychotics. Today’s result clears that threshold easily.
**Safety**
The press release gave very little safety data, and what it did include raised concerns.
Helus said no new safety signals emerged and that the drug was generally well tolerated. It also disclosed three serious adverse events (SAEs) that were judged related to HLP003.
The stock fell steeply before the market opened. An 8am ET conference call then gave much more detail on the SAEs, which seemed to calm investors. Shares opened only slightly lower and had won back much of the premarket loss.
On the call, the company said one of the three treatment-related SAEs was a suicide attempt by a patient who had not responded to the drug. Chief Medical Officer Amir Inamdar said it happened 55 days after the second dose. The patient overdosed on their antidepressant medication, was hospitalized, and was later discharged.
The company classified the event as treatment-related. Even so, Inamdar said it does not amount to a suicidality signal for HLP003. In his view, a signal would need three things: a statistically disproportionate rate, a clear timing link between drug and event, and other possible causes ruled out.
To support this, he cited:
* the patient’s underlying MDD and history of previous suicide attempts
* the boxed suicidality warning on the background antidepressant
* the time that had passed between dosing and the event
* the absence of any signal on the Columbia Suicide Severity Rating Scale (C-SSRS)
Helus gave no details on the other two treatment-related SAEs, which were simply listed as “Depression.”
Inamdar also said the placebo arm had no SAEs, and only two patients dropped out because of adverse events.
Halstead was asked whether these safety results would affect talks with the FDA or the design of a future REMS. He answered that, in short, they would not.
**Competitive positioning**
Helus is aiming its deuterated psilocin at adjunctive use in MDD patients who haven’t responded adequately to standard antidepressants. It considers this a large patient group: wider than a treatment-resistant depression (TRD) label, but narrower than a full MDD label.
Helus is targeting an NDA submission in 2028. That timing could put its approval about a year after two psilocybin products reach the market: Compass’ for TRD and Usona’s for MDD. How HLP003 would stand out in that market is unclear.
Halstead preferred to compare HLP003 with the five atypical antipsychotics approved as add-on MDD treatments. He described them as giving only a small benefit while causing side effects such as weight gain, cardiometabolic problems, and movement disorders. In the Q&A, he said Spravato could serve as a broad reference point for pricing.
Deuteration is a standard way to secure exclusivity, for example through new chemical entity (NCE) status or through patents, for a drug that might otherwise not get it. Helus has used this approach. Deuteration can change a molecule’s pharmacokinetics, but there is little evidence that it substantially changes how a psychedelic behaves clinically in people.
Using psilocin, the active metabolite of psilocybin, may still bring some benefits, and Helus highlights them. The main one, according to the company, is that psilocin is given already in its active form. This skips the body’s conversion of psilocybin to psilocin, which Helus says can improve efficiency and lower the “drug load.”
Helus has not yet released data on how long patients take to be ready for discharge, either today or with its earlier Phase 2 results. Inamdar said on the call that these data were gathered and will be published later. He added that in the mid-stage trial, acute effects lasted roughly four to six hours. It is also unclear whether Helus’ more intensive psychological support will be a commercial burden or a selling point.
**Analysis**
On efficacy, today’s results are a success for Helus. HLP003 is also the first psychedelic analog to produce Phase 3 data.
Showing clear separation from placebo despite a strong placebo response is a decisive win. On safety, the situation looks less worrying than the press release alone made it seem.
Attention now moves to EMBRACE, Helus’ second and larger Phase 3 study, which compares 16 mg with 8 mg and inert placebo. If EMBRACE also separates from placebo, with similar efficacy and a clean safety profile, Helus would be well placed to file. Management said this morning that it will not file on APPROACH alone and still aims to submit the NDA in 2028.
The open question is competitive positioning. A 2028 submission could mean launching alongside a few other psychedelic depression treatments. Helus presents its adjunctive focus as an advantage, but competitors’ drugs may also end up being used as adjuncts.
The more urgent issue may be cash. Helus had just over $170M as of September 30, 2026, and announced no financing today, so it may need to raise money soon.
sentiment 0.996
Hey there, I can help you with this.
In short, yes, you would be eligible to receive the amount of cash shown in your vested balance. It appears this is your overall balance, so the full amount, based on the screenshot, should be yours. For information on vesting, distributions after employment ends, and related topics, we highly recommend reviewing the Summary Plan Description (SPD). Since your plan is with Fidelity, if the employer has provided us with the document, you can review it online by taking the steps below on NetBenefits.com:
1. Click the 3 dots next to your plan that says "Quick Links"
2. Choose "Plan Information and Documents"
3. Select "Summary Plan Description (SPD)"
If you don't need the cash, you do have choices. This link below highlights each choice you can consider.
[Considerations for an old 401(k)](https://www.fidelity.com/viewpoints/retirement/what-to-do-with-an-old-401k)
If you have further questions about your plan or something you see in the SPD, our Workplace Investing team is happy to assist. Associates are available Monday through Friday from 8:30 a.m. to midnight ET. Please say "401(k)" when prompted by the automated system to be connected to the right group.
[Contact Us](https://www.fidelity.com/customer-service/contact-us)
Are you familiar with the implications of withdrawing early from your 401(k)?
sentiment 0.915
**BanBet Created** ▲
| Ticker | Target | Entry | Move | Expires |
|:---:|:---:|:---:|:---:|:---:|
| **NVDA** | $170.00 (above) | $157.50 | +7.9% | Sat 9:18 AM ET |
sentiment 0.250
Hi there, thanks for posting, and welcome to our sub.
We haven't received widespread reports of this particular issue. Are you still experiencing this when making the request? I noticed you did several troubleshooting steps, but as a final suggestion, I recommend uninstalling and then reinstalling the app.
If the issue persists, please get in touch with our Technical Support team to troubleshoot further. Associates are available Monday through Friday from 8:30 a.m. to 9:00 p.m. ET.
Please say "technical support" when prompted by the automated system to be connected to the right group.
[Contact Us](https://www.fidelity.com/customer-service/contact-us)
I also want to mention that every Workplace Plan is unique, so what may or may not be available by phone can vary by plan. When you called in, were you able to request a hardship withdrawal over the phone?
sentiment 0.963
Thank you for reaching out. I'm so sorry to hear about your situation.
Generally speaking, naming a spouse as the primary beneficiary and children as contingent beneficiaries is a common arrangement. However, everyone's estate planning needs are unique, so you may want to consult an estate planner or tax professional to determine whether your current setup aligns with your goals. We also offer estate planning tools to help:
[Fidelity estate planner](https://www.fidelity.com/calculators-tools/fidelity-estate-planner)
If you need to review or make beneficiary changes, you can use the page below.
[Beneficiaries (login required)](https://digitalservices.fidelity.com/navigate/ent-beneficiaries/?poe=fidcom)
Even when accounts are jointly owned, Fidelity should still be notified of the death so that account registrations and records can be updated appropriately. Our Life Events team can guide the surviving owner through any required steps and documentation. You can start the process online below, or, if you prefer, use the link on the page to call them.
[Notify Life Events](https://digital.fidelity.com/prgw/digital/journeys/loss/report-a-death)
Regarding the 401(k) plan beneficiary distributions, you will need to confirm with the plan administrator. If they are with us, our Workplace team can review beneficiaries with you. They are available Monday-Friday from 8:30 a.m. to 8:30 p.m. ET.
[Contact us](https://www.fidelity.com/customer-service/contact-us)
If you have further questions, let us know. We wish you and your family all the best. 🙏
sentiment 0.979
ET
sentiment 0.000
ET Money Ultimate SIP – Mid-Term: My experience since January 2024. Are the returns justified by its dynamic allocation strategy?
sentiment 0.649
Klamottenkauf ist nicht geteilt im WM. Jeder ET kauft für seine Kinder Klamotten, die er dann während seiner Betreuungszeit trägt. Meine Kinder haben einen vollkommen gefüllten Kleiderschrank an beiden Orten. Wenn Elternteile "gemeinsame" Ausgaben (gibt es wie erwähnt in der Regel nicht, aber OK) verweigern, macht sie entweder der andere oder man richtet mit dem Kindergeld ein gemeinsames Konto ein, von dem dann alles "gemeinsames", was das Kind betrifft, abgeht. Kinder sind immer eine massive finanzielle Belastung. Entweder durch Unterhaltszahlung oder durch Betreuung inkl. aller Anschaffungen und Kosten. Kommt ungefähr aufs gleiche raus.
sentiment 0.844